AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25148382 — intervention group
Group type: COMPARATOR
Intervention: Original tacrolimus (Prograf)
Number of subjects: 28
Study 23441068 — intervention group
Group type: EXPERIMENTAL
Intervention: NEVO stent
Number of subjects: 47
Study 23441068 — intervention group
Group type: COMPARATOR
Intervention: Xience stent
Number of subjects: 47
Study 21837439 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision of one's hand during movement planning
Number of subjects: 0
Study 21837439 — intervention group
Group type: COMPARATOR
Intervention: Virtual representation of one's initial hand location
Number of subjects: 0
Study 17418849 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol+cyproterone acetate 50mg
Number of subjects: 106
Study 17418849 — intervention group
Group type: EXPERIMENTAL
Intervention: conjugated estrogen+CA 50 mg
Number of subjects: 106
Study 17418849 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiole+CA 2mg
Number of subjects: 106
Study 17418849 — intervention group
Group type: EXPERIMENTAL
Intervention: EE+CA 52 mg
Number of subjects: 106
Study 17418849 — intervention group
Group type: EXPERIMENTAL
Intervention: EE+desogestrel
Number of subjects: 106
Study 17418849 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic estrogens (EE)
Number of subjects: 106
Study 17418849 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 106
Study 17174226 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (60 mL, fresh and deep-fried)
Number of subjects: 10
Study 17174226 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (60 mL, fresh and deep-fried)
Number of subjects: 10
Study 17174226 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil (60 mL, fresh and deep-fried)
Number of subjects: 10
Study 15353497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril therapy
Number of subjects: 9297
Study 15353497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study 11444677 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 35
Study 11444677 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 35
Study 11444677 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 35
Study 9761803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Number of subjects: 321
Study 9761803 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 321
Study 9761803 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (educational booklet)
Number of subjects: 321
Study 9761803 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and chiropractic manipulation
Number of subjects: 321
Study 9761803 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy groups (physical therapy and chiropractic)
Number of subjects: 321
Study 9761803 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 321
Study 7942982 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide at bedtime
Number of subjects: 32
Study 7942982 — intervention group
Group type: COMPARATOR
Intervention: Placebo at bedtime
Number of subjects: 32
Study 7942982 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide in the morning
Number of subjects: 32
Study 7942982 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime dosing of glyburide
Number of subjects: 32
Study 3360159 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulbocavernosus muscle graft (14 patients)
Number of subjects: 20
Study 3360159 — intervention group
Group type: COMPARATOR
Intervention: Local repair without graft (9 patients)
Number of subjects: 20
Study 31421233 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent stimulant medication use (n=53, 9%)
Number of subjects: 579
Study 30577834 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted educational and care-process-based intervention designed to improve guideline-concordant care of patients with BPPV.
Number of subjects: 0
Study 27583368 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA prime, sequential gp140 protein boost (M/M/P/P)
Number of subjects: 184
Study 27583368 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime, concurrent MVA/gp140 boost (D/D/MP/MP)
Number of subjects: 184
Study 27583368 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime, sequential MVA boost (D/D/M/M)
Number of subjects: 184
Study 27583368 — intervention group
Group type: COMPARATOR
Intervention: MVA
Number of subjects: 184
Study 27583368 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA
Number of subjects: 184
Study 27583368 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 184
Study 25091716 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 219
Study 25091716 — intervention group
Group type: COMPARATOR
Intervention: Public insurance
Number of subjects: 219
Study 22083331 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Cholecystectomy (SILC)
Number of subjects: 200
Study 22083331 — intervention group
Group type: COMPARATOR
Intervention: Four-Port Laparoscopic Cholecystectomy (4PLC)
Number of subjects: 200
Study 20060082 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg monthly oral ibandronate
Number of subjects: 132
Study 20060082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 18713883 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (20,000 KIU/kg after induction of anesthesia, followed by 20,000 KIU/kg added to pump prime)
Number of subjects: 50
Study 18713883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 50
Study 18713883 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 50
Study 15713520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Gemcitabine (VG)
Number of subjects: 86
Study 15713520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Gemcitabine plus Cisplatin (VGP)
Number of subjects: 86
Study 15713520 — intervention group
Group type: COMPARATOR
Intervention: Lung Cancer Symptom Scale (VG vs VGP)
Number of subjects: 86
Study 11966736 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I (10 ng/ml)
Number of subjects: 27
Study 11966736 — intervention group
Group type: COMPARATOR
Intervention: GH (1000, 5000, or 50000 ng/ml)
Number of subjects: 27
Study 11966736 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (200 and 5000 ng/ml) and IGF-I (10 ng/ml) for 24 and 48 h
Number of subjects: 27
Study 11966736 — intervention group
Group type: EXPERIMENTAL
Intervention: High IGFBP-3 levels
Number of subjects: 27
Study 11966736 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced mitogenic response to IGF-I in vitro
Number of subjects: 27
Study 10416910 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ROSC
Number of subjects: 26
Study 10416910 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without ROSC
Number of subjects: 26
Study 10416910 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal healthy volunteers)
Number of subjects: 26
Study 8630864 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 0
Study 8630864 — intervention group
Group type: COMPARATOR
Intervention: No screening arm
Number of subjects: 0
Study 2205455 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (500 mg three times a day)
Number of subjects: 28
Study 2205455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 380039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimazolium
Number of subjects: 3
Study 380039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 3
Study 380039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 31809439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral progesterone (400 mg twice daily for 3 days, then once daily until surgical abortion)
Number of subjects: 12
Study 31809439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 3 days, then once daily until surgical abortion)
Number of subjects: 12
Study 31809439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral progesterone
Number of subjects: 12
Study 31809439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic‐resistance exercise intervention
Number of subjects: 154
Study 29746264 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 154
Study 29746264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 154
Study 28347572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20mg, six hourly)
Number of subjects: 72
Study 28347572 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1g, six hourly)
Number of subjects: 72
Study 25880303 — intervention group
Group type: EXPERIMENTAL
Intervention: Beyond Silence, a peer‐led program customized to the healthcare workplace
Number of subjects: 200
Study 25880303 — intervention group
Group type: COMPARATOR
Intervention: Mental Health First Aid, a standardized literacy based training program
Number of subjects: 200
Study 23949035 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 10
Study 23949035 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 20803609 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response therapy (RRT)
Number of subjects: 54
Study 20803609 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Number of subjects: 54
Study 20803609 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 54
Study 19626332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-staphylococcal antibiotics for 3 weeks
Number of subjects: 23
Study 19626332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17313507 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of malaria and multivitamin supplementation
Number of subjects: 310
Study 15197788 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 1775
Study 15197788 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian Regularization Multilayer Perceptron (BR‐MLP) model
Number of subjects: 1775
Study 15197788 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of free PSA
Number of subjects: 1775
Study 11318884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray, 20 mg
Number of subjects: 28
Study 9848497 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein as half of the daily protein intake
Number of subjects: 8
Study 8135216 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% TiF4 solution applied around brackets for 60 seconds
Number of subjects: 20
Study 8135216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 2909707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 63
Study 871805 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 30% oxygen during exercise
Number of subjects: 0
Study 871805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 4 litres of oxygen/minute from nasal prongs
Number of subjects: 0
Study 871805 — intervention group
Group type: COMPARATOR
Intervention: Portable supply of liquid oxygen (Union Carbide Oxygen Walker)
Number of subjects: 0
Study 871805 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeling the oxygen walker on a light-weight shopping trolley
Number of subjects: 0
Study 31600474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 6 and Dose Frequency 6
Number of subjects: 34
Study 31600474 — intervention group
Group type: COMPARATOR
Intervention: Dose 4 × Dose Frequency 9
Number of subjects: 34
Study 31600474 — intervention group
Group type: COMPARATOR
Intervention: Dose 9 × Dose Frequency 4
Number of subjects: 34
Study 31600474 — intervention group
Group type: EXPERIMENTAL
Intervention: All formats
Number of subjects: 34
Study 31600474 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences in word learning
Number of subjects: 34
Study 29265039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway care (PC)
Number of subjects: 38
Study 29265039 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 38
Study 27082507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems engineering intervention
Number of subjects: 36
Study 27082507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 36
Study 27082507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems engineering intervention in Kenya
Number of subjects: 36
Study 27082507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control) in Kenya
Number of subjects: 36
Study 27082507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems engineering intervention in Mozambique
Number of subjects: 36
Study 27082507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control) in Mozambique
Number of subjects: 36
Study 27082507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 24955669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐session adolescent only (BI‐A)
Number of subjects: 284
Study 24955669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐session adolescent and additional parent session (BI‐AP)
Number of subjects: 284
Study 24955669 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control condition (CON)
Number of subjects: 284
Study 22999399 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group A)
Number of subjects: 56
Study 22999399 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group B)
Number of subjects: 56
Study 22999399 — intervention group
Group type: COMPARATOR
Intervention: 20mL of intra‐articular saline 0.9% (Group C)
Number of subjects: 56
Study 19321098 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Taping (ET)
Number of subjects: 27
Study 19321098 — intervention group
Group type: EXPERIMENTAL
Intervention: Inelastic Taping (IT)
Number of subjects: 27
Study 19321098 — intervention group
Group type: COMPARATOR
Intervention: No Taping (Control)
Number of subjects: 27
Study 17552381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (ASV)
Number of subjects: 10
Study 17552381 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous sleep (control)
Number of subjects: 10
Study 15110021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedotomidine
Number of subjects: 0
Study 15110021 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 15110021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11411623 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression sleeve worn for 5 days following eccentric exercise
Number of subjects: 20
Study 11411623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no compression sleeve)
Number of subjects: 20
Study 9343285 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Supplement
Number of subjects: 60
Study 9343285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9343285 — intervention group
Group type: EXPERIMENTAL
Intervention: British Mothers
Number of subjects: 60
Study 7872895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin followed by 120-hr continuous 5-FU infusion (Group A)
Number of subjects: 130
Study 7872895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administered 72 hr after the initiation of continuous 5-FU infusion (Group B)
Number of subjects: 130
Study 3146539 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 mcg/d
Number of subjects: 8
Study 3146539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29461989 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARMS intervention (sexual counseling during cardiac rehabilitation)
Number of subjects: 29
Study 28245843 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME intervention involving recruitment strategies discussion and software provision for patient eligibility extraction.
Number of subjects: 72
Study 28245843 — intervention group
Group type: COMPARATOR
Intervention: Control state (no intervention) during the initial phase before the intervention was delivered.
Number of subjects: 72
Study 26680431 — intervention group
Group type: COMPARATOR
Intervention: Standard label
Number of subjects: 92
Study 26680431 — intervention group
Group type: EXPERIMENTAL
Intervention: Text warning label
Number of subjects: 92
Study 26680431 — intervention group
Group type: EXPERIMENTAL
Intervention: Text and image warning label
Number of subjects: 92
Study 26680431 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bottle with text and image warning
Number of subjects: 92
Study 23945170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue content of marine n-3 PUFA
Number of subjects: 3440
Study 23945170 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Number of subjects: 3440
Study 23945170 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Number of subjects: 3440
Study 23945170 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosapentaenoic acid
Number of subjects: 3440
Study 21414185 — intervention group
Group type: EXPERIMENTAL
Intervention: Living arrangements for people with dementia (LAD-study)
Number of subjects: 0
Study 19040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine at breakfast
Number of subjects: 393
Study 19040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine at main mealtime
Number of subjects: 393
Study 19040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 393
Study 19040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HbA(1c) >7.0% at baseline
Number of subjects: 393
Study 19040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose
Number of subjects: 393
Study 19040645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia
Number of subjects: 393
Study 16600443 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (104.7, 105.2, or 106.1 ffu)
Number of subjects: 2464
Study 16600443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464
Study 15023613 — intervention group
Group type: COMPARATOR
Intervention: DASH type diet (OD)
Number of subjects: 94
Study 15023613 — intervention group
Group type: COMPARATOR
Intervention: Low sodium, high potassium diet (LNAHIK)
Number of subjects: 94
Study 15023613 — intervention group
Group type: COMPARATOR
Intervention: High dairy diet (HID)
Number of subjects: 94
Study 15129595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication (5 micrograms/kg 1 hr before anesthesia)
Number of subjects: 24
Study 15129595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 24
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy with ciprofloxacin (750 mg twice daily) plus amoxicillin‐clavulanate (625 mg three times daily)
Number of subjects: 353
Study 10423465 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy with ceftriaxone plus amikacin
Number of subjects: 353
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for oral therapy
Number of subjects: 353
Study 10423465 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat analysis for intravenous therapy
Number of subjects: 353
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of fever
Number of subjects: 353
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to a change in regimen
Number of subjects: 353
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for change in regimen
Number of subjects: 353
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of therapy
Number of subjects: 353
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 353
Study 10423465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 353
Study 8523657 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (1 mg.kg‐1 administered 15 minutes before operation)
Number of subjects: 26
Study 8523657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous NaCl 0.9%)
Number of subjects: 26
Study 2266262 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 2266262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 109198 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominopelvic radiation
Number of subjects: 231
Study 109198 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiation alone or followed by chlorambucil
Number of subjects: 231
Study 109198 — intervention group
Group type: EXPERIMENTAL
Intervention: None (stage IA patients with well-differentiated tumors)
Number of subjects: 231
Study 109198 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly differentiated tumors
Number of subjects: 231
Study 30817709 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 24
Study 30817709 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) control
Number of subjects: 24
Study 28376188 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation (RNI)
Number of subjects: 1664
Study 28376188 — intervention group
Group type: COMPARATOR
Intervention: Non-regional nodal irradiation (non-RNI)
Number of subjects: 1664
Study 26349479 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (LIF)
Number of subjects: 72
Study 26349479 — intervention group
Group type: COMPARATOR
Intervention: Conservative standard treatment (CST)
Number of subjects: 72
Study 26349479 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (LIF) and Conservative standard treatment (CST)
Number of subjects: 72